Short Interest in Obsidian Therapeutics (NASDAQ:OBX) Rises By 125.6%

Obsidian Therapeutics (NASDAQ:OBX) was the recipient of a large increase in short interest in August. As of August 31st, there was short interest totaling 81,457 shares, an increase of 125.6% from the August 15th total of 36,102 shares. Approximately 0.1% of the shares of the company are short sold. Based on an average daily volume of 227,768 shares, the days-to-cover ratio is currently 0.4 days.

Wall Street Analyst Weigh In

A number of research firms have recently commented on OBX. Piper Sandler assumed coverage on Obsidian Therapeutics in a research report on Wednesday, August 5th. They set an “overweight” rating and a $42.00 target price on the stock. Weiss Ratings started coverage on shares of Obsidian Therapeutics in a research report on Wednesday, September 2nd. They set a “sell (d-)” rating for the company. William Blair started coverage on Obsidian Therapeutics in a research report on Wednesday, September 9th. They issued an “outperform” rating on the stock. Lifesci Capital initiated coverage on shares of Obsidian Therapeutics in a research note on Tuesday, August 18th. They issued an “outperform” rating and a $43.00 price target on the stock. Finally, TD Cowen began coverage on Obsidian Therapeutics in a report on Thursday, August 6th. They issued a “buy” rating for the company. Four equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $42.50.

Obsidian Therapeutics Stock Performance

NASDAQ:OBX traded up $0.24 during trading hours on Tuesday, reaching $18.34. 223,584 shares of the stock were exchanged, compared to its average volume of 205,164. Obsidian Therapeutics has a twelve month low of $14.57 and a twelve month high of $49.97.

Obsidian Therapeutics Company Profile

Obsidian Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing novel protein-regulation technology to develop engineered TIL cell therapies for the treatment of patients with solid tumors. Obsidian Therapeutics Inc is based in CAMBRIDGE, Mass.